| chronic pain (diagnosis)
Belbuca vs Mitigo
Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).Deep comparison between: Belbuca vs Mitigo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMitigo has a higher rate of injection site reactions vs Belbuca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mitigo but not Belbuca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Belbuca
Mitigo
At A Glance
Buccal film
Every 12 hours
Partial opioid agonist
Epidural/intrathecal infusion
Daily (continuous infusion)
Opioid agonist
Indications
- chronic pain (diagnosis)
- chronic pain (diagnosis)
Dosing
chronic pain (diagnosis) 75 mcg buccal film once daily or every 12 hours for opioid-naive patients, titrated in increments of 150 mcg every 12 hours no more frequently than every 4 days to a maximum of 900 mcg every 12 hours; initial dose for opioid-experienced patients: 150 mcg every 12 hours (30-89 mg oral MSE) or 300 mcg every 12 hours (90-160 mg oral MSE).
chronic pain (diagnosis) - Epidural Initial 3.5-7.5 mg/day (opioid-naive) or 4.5-10 mg/day (opioid-tolerant) via continuous epidural infusion; dose requirements may increase to 20-30 mg/day; titrate individually to adequate analgesia.
chronic pain (diagnosis) - Intrathecal Initial 0.2-1 mg/day (opioid-naive) or 1-10 mg/day (opioid-tolerant) via lumbar intrathecal infusion; intrathecal dose is typically 1/10 of epidural dose; doses above 20 mg/day should be used with caution.
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity (e.g., anaphylaxis) to buprenorphine
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or absence of resuscitative equipment
- Concurrent use of MAOIs or use within the last 14 days
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to morphine (e.g., anaphylaxis)
- Infection at the neuraxial injection or microinfusion site
- Concomitant anticoagulant therapy (neuraxial administration)
- Uncontrolled bleeding diathesis (neuraxial administration)
- Any concomitant therapy or medical condition rendering epidural or intrathecal administration especially hazardous
Adverse Reactions
Most common (>=5%) Nausea, constipation, headache, vomiting, fatigue, dizziness, somnolence
Serious Addiction, abuse, and misuse; life-threatening respiratory depression; interactions with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; QTc prolongation; hepatotoxicity; anaphylactic/allergic reactions; seizures
Postmarketing Serotonin syndrome, adrenal insufficiency, anaphylaxis, androgen deficiency, hyperalgesia and allodynia, dental decay (caries, tooth fracture, and tooth loss), hypoglycemia, opioid-induced esophageal dysfunction
Most common Nausea, vomiting, constipation, pruritus, urinary retention, dizziness, headache, myoclonus, anxiety, confusion
Serious Respiratory depression, myoclonus, inflammatory masses, seizures, severe hypotension, adrenal insufficiency, serotonin syndrome, anaphylaxis
Postmarketing Androgen deficiency, hyperalgesia and allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Pharmacology
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor; it produces analgesia by binding with high affinity to opioid receptors on neurons in the brain and spinal cord and, unlike full opioid agonists, exhibits a dose-ceiling effect on respiratory depression.
Morphine is a full opioid agonist selective for the mu-opioid receptor that produces analgesia through CNS opioid receptors in the brain and spinal cord; it also causes respiratory depression by direct action on brain stem respiratory centers and reduces GI motility through smooth muscle effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Belbuca
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
Mitigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Belbuca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Mitigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Belbuca
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Mitigo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Belbuca.
No savings programs available for Mitigo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BelbucaView full Belbuca profile
MitigoView full Mitigo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.